Genomic and clinical correlates of belzutifan treatment in renal cell carcinoma (RCC): A retrospective analysis of 240 RCC patients.
Yu-Wei Chen(University of California San Diego), Rana R. McKay(UC San Diego Health System), Brent S. Rose(University of California San Diego), Shayan Nazari(National Institutes of Health), Marc Machaalani(Dana-Farber Cancer Institute), Sumanta Kumar Pal(City Of Hope National Medical Center), Aditya Bagrodia(University of California San Diego), Pedro C. Barata(University Hospitals Seidman Cancer Center), Rashad Nawfal(Dana-Farber Cancer Institute), Andrew Elliott(Caris Life Sciences (United States)), Norm Smith(Caris Life Sciences (United States)), Neeraj Agarwal(University of Utah), Liliana Ascione(Dana-Farber Cancer Institute), Toni K. Choueiri(Dana-Farber Cancer Institute), Ninad Kulkarni(Caris Life Sciences (United States))
Cited by 1
Related Papers
Normal Tissue Complication Probability Modeling of Acute Hematologic Toxicity in Cervical Cancer Patients Treated With Chemoradiotherapy
|International Journal of Radiation Oncology*Biology*Physics|2010|194
Clinical Outcomes of Intensity-Modulated Pelvic Radiation Therapy for Carcinoma of the Cervix
|International Journal of Radiation Oncology*Biology*Physics|2010|165
Extracellular matrix dynamics in cell migration, invasion and tissue morphogenesis
|International Journal of Experimental Pathology|2019|120
Preliminary safety, pharmacokinetics and clinical activity of DFF332, an oral HIF2α inhibitor, as monotherapy in a phase 1 dose escalation study in patients with advanced clear cell renal cell carcinoma.
|Journal of Clinical Oncology|2024|9
Adjuvant Atezolizumab in Patients with Sarcomatoid Renal Cell Carcinoma: A Prespecified Subgroup Analysis of IMmotion010
|European Urology Oncology|2024|4